Table 3.
The MPN grade 1 fibrosis phenotype.
| PMF (N: 33) | PV/ET (N: 58) | Total (N: 91) | p value | |
|---|---|---|---|---|
| Median age | 63 yrs | 55 yrs | 59 yrs | 0.005 |
| Gender | ||||
| Male | 25(76%) | 32(55%) | 57(63%) | 0.05 |
| Female | 8(24%) | 26(45%) | 34(37%) | |
| JAK V617F+ | 16/33 (49%) | 40/58(69%) | 56/91 (62%) | 0.02 |
| Median Hgb (g/dL) | 11.1 (7.9–16.4) | 12.8 (range 8.0–19.8) | 12.2(7.9–19.8) | 0.24 |
| Median WBC(X10 (9)) | 26.9(1.3–188) | 8.9 (3.5–51.3) | 10.8(1.3–188) | 0.02 |
| Median platelet (X10 (9)) | 179(18.0–1194) | 505(67–2286) | 370(18–2286) | <0.001 |
| Leukoerythroblastic blood smear | 15/33 (45%) | PV: 17 ET: 5 Total: 22/58 (38%) |
37/91 (41%) | 0.48 |
| Splenomegaly (cm below costal margin) | 18/33(55%) | 25/58(43%) | 43/91(48%) | 0.29 |
| Median: 10 | Median: 6 | Median: 4 | ||
| Transfusion dependence | 6/33(18%) | 2/58 (4%) | 8/91 (9%) | 0.02 |
| Presence of ≥1 symptom | 17/33(52%) | 33/58(57%) | 50/91 (55%) | 0.62 |
| DIPSS risk intermediate 2 or higher | 13/33 (39%) | 17/58(29%) | 30/91 (33%) | 0.32 |
| 2 or more prior therapies | 9/33 (27%) | 36/58(62%) | 45/91 (49%) | 0.001 |
| Median follow up time (yrs) | 1.9 (0.1–9.8) | 5.7 (0–34.5) | 3.1 (0–34.5) | <0.001 |